Pharma QMS: Quality Management Software for Pharmaceutical Manufacturing

GMP-ready. Inspection-ready. Built for pharma.

Pharmaceutical QMS Software: A GMP-Aligned Platform for Batch Records, Deviations, CAPA, and Regulatory Inspection Readiness

Pharmaceutical quality professionals carry a specific set of regulatory obligations that general-purpose quality management systems were not designed to address. Every batch of drug product requires a complete batch production record. Every deviation from a validated process requires a documented investigation with root cause determination. Every out-of-specification test result triggers an investigation before a batch disposition decision can be made. Equipment qualification and process validation documentation must be maintained, current, and available to FDA investigators on demand.

eLeaP’s pharmaceutical QMS software is built around these requirements rather than adapted to them. This page covers the GMP-specific capabilities of the platform, the ICH Q10 and 21 CFR Part 211 frameworks that govern pharmaceutical quality systems, what a pharma-grade CAPA process requires, how integrated training satisfies 21 CFR Part 211.68, and how eLeaP approaches computerized system validation support.

The Regulatory Framework: ICH Q10, 21 CFR Part 211, and EU GMP

Pharmaceutical quality systems operate under three overlapping international frameworks. Understanding how they interact is a prerequisite to evaluating whether a pharmaceutical QMS software actually satisfies the regulatory environment.

ICH Q10 Pharmaceutical Quality System

ICH Q10 is the primary international standard for pharmaceutical quality systems, developed by the International Council for Harmonisation and adopted by the FDA, EMA, and health authorities across major regulated markets. ICH Q10 Section 3 defines the four principal elements of a pharmaceutical quality system: knowledge management, quality risk management, corrective and preventive action, and change management. Management review is an additional element covered in Section 3.5.

ICH Q10 Section 3.2 covers knowledge management: the organisation must capture, maintain, and apply knowledge accumulated through product and process development, technology transfer, commercial manufacturing, and product discontinuation. In practice, this means that batch record data, deviation history, process validation data, and change history must be accessible as a connected knowledge base rather than siloed in separate systems.

ICH Q10 Section 3.3 covers quality risk management: decisions about product quality must be supported by risk assessments that are documented, reviewed, and communicated. Risk assessments for deviations, change controls, and supplier qualifications must connect to the quality record that triggered them.

ICH Q10 Section 3.4 covers CAPA: corrective and preventive actions must address the root cause of a detected nonconformance, and effectiveness must be verified. This section is the ICH counterpart to the FDA 483 observation pattern on inadequate CAPA systems.

ICH Q10 Section 3.5 covers change management: changes to processes, equipment, facilities, systems, and suppliers require a structured evaluation, impact assessment, approval, and post-implementation review. Changes that affect the validated state trigger revalidation requirements.

ICH Q10 Section 3.6 covers management review: senior management must review the pharmaceutical quality system at defined intervals to assess performance and drive continuous improvement. The review requires data on CAPA status, deviation trends, audit findings, change history, and product quality indicators.

21 CFR Part 211 — FDA Current Good Manufacturing Practice

21 CFR Part 211 is the FDA’s CGMP regulation for finished pharmaceuticals. Its requirements for laboratory controls (Subpart I), production and process controls (Subpart F), and records and reports (Subpart J) define the documentation and procedural obligations that FDA investigators review during inspections. Part 211.192 requires that all drug product production and control records be reviewed and approved before batch release. Part 211.192 also requires that any unexplained discrepancy or failure of a batch to meet specifications be thoroughly investigated — the OOS investigation requirement.

EU GMP Annex 11 and Chapter 4

European facilities regulated under EU GMP face additional requirements under Annex 11 (Computerised Systems) and Chapter 4 (Documentation). Annex 11 governs electronic records systems used in GMP contexts, including audit trail requirements, access control, and data integrity provisions. Chapter 4 governs documentation practices, including document control, change records, and batch record completeness. eLeaP’s audit trail, role-based access configuration, and electronic signature workflow address the Annex 11 and Chapter 4 requirements applicable to a QMS platform.

GMP-Specific Capabilities: What Pharma Requires That Other Industries Do Not

The operational requirements of pharmaceutical manufacturing impose record-keeping and investigation obligations that have no direct parallel in general manufacturing or service industry quality systems. Each capability below addresses a GMP requirement that a general-purpose QMS handles inadequately or not at all.

Batch Production Records

21 CFR Part 211.188 requires that batch production and control records include a complete reproduction of the master batch record, documentation of all weighings and measurements, identification of equipment used, in-process testing results, and identification of personnel performing each step. The batch record must demonstrate that the batch was manufactured in accordance with the master formula and standard operating procedures.

eLeaP’s batch record management allows batch production records to be created from the master batch record template, with step-by-step execution tracked against the master. Each executed step captures the operator, the timestamp, the equipment identifier, and the recorded values. Deviations from the master — out-of-range weights, missed steps, equipment substitutions — generate deviation records directly from within the batch execution record. The batch record and any associated deviations are reviewable as a unified package by the batch release reviewer before the batch disposition decision is made.

Deviation Management and Investigation

Every departure from a validated process, an approved procedure, or a batch record step requires a documented deviation investigation. The investigation must determine whether the deviation had an actual or potential impact on product quality, identity, strength, purity, or potency. The impact assessment determines whether the batch can proceed to release, requires additional testing, or must be rejected.

eLeaP’s deviation management workflow categorises deviations by type — planned or unplanned — and by severity. The investigation record captures the description of the deviation, the immediate impact assessment, the root cause determination, and the disposition recommendation. When the deviation requires a CAPA, the CAPA record is initiated from within the deviation record, preserving the link between the deviation event and the corrective action taken. Recurrent deviations on the same process step or equipment unit surface in trending reports, enabling proactive identification of systemic issues before they generate a regulatory observation.

Out-of-Specification Investigation

FDA’s guidance on OOS laboratory results requires a structured two-phase investigation. Phase 1 is the laboratory investigation: the analyst and supervisor review the test for analyst error, instrument malfunction, or sample preparation error. If Phase 1 identifies a root cause, the OOS result may be invalidated and the test repeated. If Phase 1 finds no assignable cause, Phase 2 is the full-scale investigation encompassing manufacturing review, additional testing, and batch impact assessment.

eLeaP’s OOS investigation workflow enforces the two-phase structure. Phase 1 fields capture the laboratory review findings with supervisor sign-off. The system prevents advancement to Phase 2, invalidation of the result without documented Phase 1 completion. Phase 2 records connect to the batch record for the affected lot, the deviation record if a manufacturing root cause is identified, and the CAPA if systemic corrective action is required. OOS investigations that exceed defined turnaround time targets generate escalation notifications to quality management.

Equipment Qualification and Process Validation

21 CFR Part 211.68 requires that equipment used in drug product manufacturing be of appropriate design, adequate size, and suitably located to facilitate operations and cleaning. Equipment qualification — Installation Qualification, Operational Qualification, and Performance Qualification — documents that the equipment was installed correctly, operates within specified parameters, and performs consistently in the process application. Process validation under FDA’s 2011 guidance requires Stage 1 (process design), Stage 2 (process qualification), and Stage 3 (continued process verification) documentation.

eLeaP manages qualification and validation documentation within the quality record structure. IQ, OQ, and PQ protocols and reports link to the equipment record. Requalification triggers — scheduled interval, change control, or deviation event — generate work orders within the system. Process validation documentation, including protocols, executed data, and summary reports, is organized within the product record structure. When a change control affects a validated process, the change record identifies the revalidation requirement and the validation documentation updates as part of the change closure workflow.

CAPA in Pharmaceutical Manufacturing: Why FDA 483 Observations Keep Appearing

CAPA-related observations are among the most frequently cited findings in FDA warning letters and Form 483s. The pattern is consistent: the quality system contains CAPA records, but those records document actions that were assigned rather than actions that were verified effective. The FDA’s expectation under 21 CFR Part 211 and ICH Q10 Section 3.4 is that a CAPA system demonstrates prevention of recurrence — not just documentation of intent.

An effective pharmaceutical CAPA system requires three things that most implementations fail to deliver structurally. First, root cause analysis must be documented at sufficient depth to support the corrective action taken. A root cause statement of “operator error” does not support a corrective action of retraining unless the investigation identifies which specific knowledge or procedural gap the operator experienced and how the training will address it. eLeaP’s CAPA record requires root cause categorisation, supports structured analysis documentation (5-Why, fishbone), and links the root cause explicitly to each corrective action item.

Second, effectiveness verification must be defined at the time the CAPA is opened, not assessed retrospectively after the corrective action is complete. The verification criteria — a defined monitoring period with no recurrence, a confirmed reduction in the associated deviation rate, confirmation that the process change was implemented and trained on — must be specified in advance. eLeaP’s CAPA workflow requires effectiveness criteria to be documented before the corrective action stage begins, and prevents the CAPA from advancing to closed status until those criteria are met and documented.

Third, prevention of recurrence requires that the corrective action address not just the immediate event but the conditions that allowed the event to occur. When a CAPA root cause identifies a gap in the control system — a missing in-process check, an inadequate specification limit, a training program that did not cover a specific scenario — the corrective action must address the control system gap. eLeaP’s CAPA record links to the relevant SOP, specification, or training matrix element that the corrective action modifies, so the connection between the event and the systemic change is traceable in a single record chain rather than in a narrative summary.

Integrated Training in Pharma: 21 CFR Part 211.68 and ICH Q10 Competency Requirements

In pharmaceutical manufacturing, training is not an operational preference — it is a regulatory requirement with inspection consequences. 21 CFR Part 211.68 requires that personnel engaged in the manufacture, processing, packing, or holding of drug products have education, training, and experience to enable them to perform their assigned functions. FDA investigators reviewing training compliance during an inspection expect to find records showing that each person performing a GMP function is trained on the current version of the procedures governing that function.

ICH Q10 extends this requirement with a competency-based framework. Section 2.2 of ICH Q10 requires that the pharmaceutical quality system support the development and management of human resources, including competency assessments linked to the quality system. A training completion record that shows an employee has read an SOP does not demonstrate competency. A training record that shows the employee completed the training, passed a knowledge assessment, and is assigned to a role that requires that procedure — and that the training version matches the current SOP revision — demonstrates competency in the ICH Q10 sense.

eLeaP’s integrated QMS and LMS deliver this directly. When an SOP governing a GMP process is revised, the system automatically identifies every role assigned to that procedure and creates retraining assignments with a due date calculated from the configurable retraining window. The training assignment carries the document version number. Completion records link to the specific document revision. When an FDA investigator requests evidence that production staff is trained on current procedures, the query runs against live QMS and training data simultaneously and returns a single report showing, for each employee, the current SOP version, the training completion date, the assessment score, and whether the training record matches the current effective revision.

CAPA-triggered training is structurally enforced. When a CAPA corrective action requires retraining on a revised procedure, the retraining assignment is created within the CAPA record. The CAPA cannot advance to effectiveness verification until the linked training completions are confirmed. This eliminates the most common failure mode in pharmaceutical CAPA systems: a corrective action that included retraining was marked complete without evidence that the retraining occurred.

Computerized System Validation: What eLeaP Provides and What You Are Responsible For

Every pharmaceutical quality professional evaluating a new software platform will ask the same question: Is this system validated? The answer requires distinguishing between what the software vendor provides and what the regulated user is obligated to validate in their own environment under 21 CFR Part 11, EU Annex 11, and the FDA’s general principles for computer system validation.

eLeaP provides a validation support package that includes the Installation Qualification protocol and report for the hosted environment, the Operational Qualification protocol covering core system functions against documented specifications, and the system’s technical architecture documentation. The IQ and OQ documentation is available to customers as part of the validation support package and is intended to support the customer’s own validation program.

The regulated user is responsible for the Performance Qualification — demonstrating that the system performs correctly in their specific configured environment for their specific intended uses. The PQ must cover the workflows, configurations, and record types the customer has implemented. eLeaP provides PQ protocol templates and configuration documentation to support the customer’s PQ execution. The customer’s quality unit owns the PQ execution, the test results, and the validation summary report.

eLeaP’s change control process for platform updates provides advanced notification of system changes that may affect the validated state. Customers receive change notification documentation that supports the impact assessment step of their change control procedure before a platform update is deployed. This allows the customer’s quality unit to assess whether a platform change requires revalidation activity in the customer’s environment before the change is effective.

21 CFR Part 11 compliance — electronic records and electronic signatures — is addressed at the platform architecture level. The eLeaP audit trail captures the who, what, when, and reason for every record creation, modification, or deletion. Electronic signatures require dual-factor confirmation. Audit trail records are tamper-evident and cannot be disabled by users. These capabilities are documented in the validation support package with traceability to the Part 11 requirements they address.

Evaluating Pharmaceutical QMS Software: What the Selection Criteria Should Be

The pharmaceutical QMS software market includes platforms that market themselves to pharma buyers without demonstrating GMP-specific workflow depth. SimplerQMS and DotCompliance hold some pharma keyword positions, but neither demonstrates the batch record, OOS investigation, or validation support architecture that regulated pharmaceutical manufacturers require. When evaluating pharmaceutical QMS software, the relevant questions are workflow-specific.

eLeaP’s answers to all six questions are yes, demonstrable in a scoped platform walkthrough configured for pharmaceutical manufacturing. Request a demo that covers your specific workflows — deviation management, OOS investigation, CAPA with effectiveness verification, or batch record execution — at eleapsoftware.com.

Related resources: